Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BT-205
- Development stage
- Preclinical
- Lead developer
- Bridge Therapeutics
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
BT-205 is an investigational, sublingual fixed-dose analgesic combination developed by Bridge Therapeutics for moderate-to-severe chronic pain in opioid-experienced patients. It combines buprenorphine, a partial agonist at the mu-opioid receptor, with meloxicam, a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes, including COX-2. Bridge Therapeutics identifies BT-205 as a patented combination covered by U.S. Patent 8410092 and has also referred to the product as Bucam. (bridgetherapeutics.com)
- Brand names
- Bucam
- Other names
- buprenorphine + meloxicambuprenorphine-meloxicam
02
Targets
Beyond the preview
Go deeper on BT-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BT-205.